EGFR and non-small cell lung carcinoma: According to the cost-effectiveness analysis by Giuliani and Bonetti, osimertinib is more cost-effective than the other first- and second-generation EGFR-TKIs for first-line treatment of patients with advanced NSCLC with EGFR mutations [41].